<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 53 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page52.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=53">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 53 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 53</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=53"><img src="../thumb/53.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>22 / 2020-04                                          Central Nervous System - 1.4.9 / 1.4.10 / 1.5 / 1.5.1 / 1.5.2
   myasth.grav., exopthalmos, trans.scotoma, excess. salivat., gastrit.,   Warnings and special precautions: Cons. risk/ benef.in
   acquir.nephrogen.diab.insipid., glycosur., albuminur., acne/exacerbat.  ac.alchol./card.dis.esp.arrhythm./imp. hepat. & ren.funct, digoxin tox-  1.5  Anti-psychotics
   thereof, hair thin., alopec., skin reacts., musc.hyperirritabil./-weakn.   ic., elderly, may antagon. activit.of anti-epilept.by low.convuls. thresh.,
   /-rigid., twitch., hypo-/hyperthyroid., hyperparathyroid., parathyroid   monit.concom.phenytoin.& concom. antihypertens., poss warfar.dos.
   adenoma, weight gain, trans.hyperglycaem., hypercalcaem. /-mag-  incr., monit.suicide risk esp.dur early antidepress.ther., grad.withdr.  1.5.1  Phenothiazines
   nesaem., lethargy, asthen., headache, diffuse non-tox.goitre format.  Drug interactions: Potent act.of barbits./musc. relax./ antidyski-
   Warnings and special precautions: Li toxic., concom.diuret./  netics/volatile anaesth./ phenothiaz./ antihistamin./pimozide/ se-
   NSAID ther., monit.Li lev.more freq. if NSAID init./discont., discont.  dat.& anti-depress. incl.alcoh., poss.interacts with MAOIs report.,   LARGACTIL, Sanofi-Aventis [P/S]
   ther.24 hrs. prior to surg., euthyroid/prompt & accurate plasma Li-  neurotox.S/E poss.promote with concurr. tricycl./ relat.anti-depress.&   Chlorpromazine HCl.
   determ. facilit.to be avail.bef.init.ther., rais.ADH plasma lev., plasma   Li, amiodarone incr. risk of ventric.arrhythm., elev.ser.lev.of digox./   Indications: Excitem., agitat., other psychomot. disturbs.in schizo-
   lev.not to exceed 2,0 mmol/L dur.ac.phase & 1,5 mmol/L dur.maint.  phenytoin & poss.other hydantoin anticonvuls./ carbamazep., anti-  phren., reduc.manic phase of manic depress.condits., contr.hyperki-
   ther, perman. kidn. chang. & imp.ren.funct.with longt. treatm. poss.   convuls.effs.of antiepilept. poss.antagon., occas.reports of seroton.  net.states & aggress., psychiatr.condits.for control of anx.& tens.,
   enhanc.with high ser.conc., minim.effect. dos. to be used., only   syndr.& convuls.esp.when assoc.with other psychotrop. meds., CNS   intractable hiccup.
   maint.on treatm.aft.3-5 yrs.if benef. persists, monit.thyroid funct.at   depress.enhanc.by clonidine, poss. incr.hypotens.risk with antihyper-  (S5) TABS, [P/S] B511, 12, 13.
   3 mnthly interv., monit.plasma Li lev.at least every 10 wks., tol. incr.  tens., CYP3A4 inhibits.may limit trazodone eliminat., CYP3A4 induc.  735868-019: 25 mg, 56, R130,98
   dur.ac.man.phase decr.marked.when manic sympts.subside, adeq.  may reduc. trazodone plasma conc.  735876-003: 50 mg, 56, R228,83
   fluid intake esp.dur. init. stabilis. per., not for pts. on salt-free diet,   735884-006: 100 mg, 56, R388,66
   protract. sweat./diarrh.decr.tol.& supplem.fluid & salt advis., con-  BRINTELLIX, Lundbeck [P/S] &  Dosage: Indiv. Init: oral 25-50 mg 3xdly., grad.incr.as necess. Dly.dos.
   com.diurets.& low sod.diets dur. pregn., epidemiolog.evid.suggest.   Vortioxetine hydrombromide  of 75 mg may be giv.at night.
   harmf.effs.dur. pregn., cross.placenta barr.& pres.in breast milk, poss.   Indications: Maj.depress.& relapse risk reduc.  N&V: 10-25 mg 4-6 hrly.
   thyroid involvem., elderly, use in childr.not recomm., avoid mark.  (S5) TABS, 48/1.2/0429, 0430, 0432  Childr: 500 µg/kg bm.4-6 hrly orally.
                                                                             1
   chang.in diet.salt intake.   721190-001: 5 mg, 28, R409,80  Psych.condits: Childr.over 5 yrs:  / 3-½ adult dose. Dly dos not
   Drug interactions: ACE inhibit.& angiotens. recept. block.raise ser.  720751-001: 10 mg, 28, R409,80  to exceed 40 mg for childr.1-5  yrs.or 75 mg in childr.over 5 yrs.
   lev., nephrogen. diabet. insipid.sympt. with concom. TCAs, reduc.  720752-001: 20 mg, 28, R444,95  Contraindications: Pre-exist.CNS depress., coma, bone mar-
   clear.with diurets., acetazolamide reduc.ser.lev., poss.incr. ser. lev.  Dosage: Adults: Init.10 mg once dly. Dos.may be incr.to max.20 mg   row suppress., phaeochromocyt., imp. liv./kidn./CV/ cerebrovasc./
   with NSAID’s poss.result.in Li-toxic., imp. ren. eliminat./incr.ser.Li   dly or reduc.to min.of 5 mg dly depend. on pt.respons. Dos.incr.should   resp.funct., clos. angle glauc., parkinson., diab.mellit, hyperthy-
   conc.with metronidazole, incr. S/E risk with antidepress.eg.SSRI’s/  be in per.of not less than one wk.of treatm.if reqd. Consid. decr. dos.  roid., myasth.grav., prostat.hypertrophy, epilepsy, safety in pregn.&
   TCA’s, neurotoxic. with carbamazepine/clonazepam & poss. phenytoin   for pts.unable to toler.high.dos. Aft. sympts.resolve 6 mnths.treatm.  lactat.not est.
   without Li ser.lev.change, methyldopa incr.toxic.with ser.lev.change,   recomm.for consolidat.of antidepress.respons. May be stop. abrupt.  Side effects: QT-prolongat.& potent.incr. torsades de pointes risk,
   incr.S/E risk with concom.other anti-psychot.esp. extrapyramid.   without need for grad.dos.reduct.  bld.dyscras., hypersens. reacts., alter.endocr.& metabol.functs., imp.
   sympt., unpredic.neurotox.S/E & bradycard. potent.with diltiazem /  Elderly: Init.5 mg once dly. Dos.may be incr.to 10 mg dly depend. on   body temp. regulat., delirium, agitat., cataton.-like states, insomn.,
   verapamil without ser.lev.change, ser.lev.reduc.with caffeine/ other   pt.respons. Limit.data on dos.exceed.10 mg dly.  drowsin., nightm., depress., extrapyramid. dysfunct., result.disords.
   xanthine derivat.& Na salts.  Contraindications: MAOI’s, concom. linezolid.  incl.ac.dyston., parkinsonism-like syndr., acathis., late effs.incl. tar-
   See also MDR page 163.       Side effects: Very comm: Naus. Comm: Abnorm. dreams, dizzin.,   dive dyskines., perioral trem., neurolept. malign. syndr., skelet.muscle
                                headache, somnol., sedat., insomn., diarrh., constip., vomit., prurit.,   damage, myoglobinur.poss. lead. to ren.fail., EEG chang., convuls.,
                                fatigue, naso-pharyngit., influenza, decr.appet., back pain, arthralg.,   skin/eye pigment deposit.with prolong.ther., corn.& lens opacit., pig-
                                                              ment retinopathy, miosis, photosens., tachycard., ECG chang., card.
   1.4.10  Others               hyper-hidros. Uncomm: Flush., night sweats. Unknown freq.: Ana-  arrythm., hypotens., nas. congest., liv.funct.test abnorm., cholestat.
                                phylact. react., hyponatraem., seroton.syndr., NMS, haemorrh. incl.
   ASPEN TRAZODONE (MDR Listing)  contus./ecchymos./epistax./GI or vag. bleed., angioed., urticar., rash,   jaund., liv.injury, SLE-like syndr., ejaculat.inhib., impot., priapism.,
                                                              antimuscar.effs., loc.reacts.for inj.,dry mouth, constipat., micturit.
   BRINTELLIX (MDR Listing)     sex.dysfunct., hyponatraem.   diffic., vis. disturbs., mild.withdr.sympts.follow.abrupt withdr. aft.
                                Warnings and special precautions: Safety & effic.in pregn./childr.
   ASPEN TRAZODONE, (Pharmacare) Aspen Pharmacare [P/S] &  und.18 yrs.not est., safety in lactat. not est., excret.in milk of lactat.  prolong.ther., sudd.death.
   Trazodone HCl.               rats., Suicid. behav. more freq. observ.in childr.& adolesc.treat. with   Special precautions: Low.seiz.threshold of epilept. receiv.anticon-
   Indications: Depress., mixed anx.& depress.  other antidepress., incr.risk of suic.thoughts/ self-harm/suic., monit.  vuls., exacerbat.QT prolongat. in pres.of bradycard./hypokalaem./
   (S5) CAPS, 37/1.2/0491, 0492  pts.caref.until signif.remiss. occurs, pts.with suic.-relat.events hist./  congenit./ acquir.QT prolongat., elderly, incr.risk of cerebrovasc.
   714596-001: 50 mg, 100, R458,41  exhibit. suicid. ideat.bef.init.treatm., monit.pts.esp.dur. early ther.&   events, stroke risk fact., others meds that produc.postur.hypotens.,
   714597-001: 100 mg, 100, R880,01  dos.chang.for clinic.worsen./suicid. ideat./ -behav., elderly, seiz.  may prolong labour, excret. in breast milk, debilit., may mask OD
   Dosage: Dly.dos.admin.in 3 div.dos.  hist./unstab.epilep., other meds. low.seiz.thresh., ECT, discont.ther.  sympts. of other agents/ GI obstruct., extrem.of body temp., reg.
   Adults: Optim.dos: 300-400 mg/day. Suggest.init dos: 150 mg/  if pt. develop.seiz./incr.in seiz.freq./ pt.enters manic phase, mania/  eye.exam.with long term ther., avoid. dir.expos.to sunlight, monit.
   day in1st wk.incr.to 300 mg/day or high.accord.to clinic.respons.  hypoman.hist., monit.for S&S of NMS/ seroton.syndr.with concom.  haematologic. param./ BP, avoid abrupt withdr.
   (600 mg dos.report.).        linezolid, concom. alcoh.not advis., sev.ren.insuff., no studies in sev.  Drug interactions: May reduc.antihypertens.act. of guanethidine
   Mix.anx.& depress: Recomm.init.dos: 100-150 mg/ day. When   hepat.impairm., concom.strong CYP2D6 inhibits./broad cytochrome   & other adrenerg neurone block., may potent.adverse effs.of other
   depress.is predomin.sympt dly.dos.of 300-400 mg poss.reqd.for   P450 induc., consid. poss.SSRI assoc.persist.pulm.hypertens.in   antimuscarin. incl. antimuscarin.antiparkinson.agents given to treat
   satisfact. respons.          newborns due to relat.mechan.of act., discont. ther. immed.in case   phenothiaz.induc.extrapyramid.effs., neurolept. with dopamine-block.
   Contraindications: Ac.recov.phase of MI, combin. use with other   of seroton.syndr.sympt.incl. ment. stat.chang./autonom.instab./neu-  activ.& dopaminerg. meds.used to treat parkinson.poss. mutual. an-
   psychotrop.drugs should only be undertak.with due recognition of the   romusc. disords. &/GI sympt., hyponatraem.in risk pts. e.g. elderly/   tagonist., metoclopram may incr.risk of neurolept.-induc.extrapyramid.
   poss. of potentiat., safety in pregn./lactat.& childr.not est.  cirrhot.pts./concom.meds.caus. hyponatraem., cons.discont.ther.in   effs., antiarrythm. that prolong QT-interv.may incr.likelihood of ventric.
   Side effects: CNS effs., dizzin., headache, dry mouth, GI dis-  sympt. hyponatraem. & init.appropr.treatm., anticoags. &/ meds.   arrhythm., CNS depress.enhanc.by other CNS depress.incl.alcoh.
   turbs., unpleas.taste, musc.trems., confus., hypotens., allerg.skin   known to aff.platel.funct./known bleed. tendenc./ disords., consid.  STEMETIL, Sanofi-Aventis (Pty) Ltd
   reacts., fast/slow heart beat, priapism, unus.excitem., blurr.vis.,   low.dose with concom. strong CYP2D6 inhibits., concom.bupropion/  See Section 1.8
   arthralg., unus.tiredn./weakn., bld.dyscras., jaund., hepatocell.
   damage, hyponatraem.poss.due to inappropr. secret.of antidiuret.  Li/ tryptophan /other meds.known to low.seiz.thresh., incr. bleed.risk
                                potent.poss.due to interact.with concom. oral anticoags./antiplatel.
   horm.esp.elderly.
                                Interactions: Seroton.syndr.risk with MAOI’s/ serotonerg.meds.incl. 1.5.2
   Special precautions: Cons.risk/benef: ac. alchol./ card.dis.esp.  meds., no exper. with concurr.ECT  Butyrophenones
   arrhythm./imp.hepat./ren. funct, digoxin toxic., monit.concom.phe-
   nytoin., concom. antihypertens., cont.lact.  triptans/antipsychot./other dopamine antagon., concom.St.John’s   SERENACE, Pfizer [P/S]
   Drug interactions: Depress.effs.of alcoh./CNS depress. & some   Wort poss. high.adverse react.incid., incr. AUC with bupropion/
   antihypertens.poss.potent., poss. incr. hypotens.risk with antihyper-  ketoconazole/fluconazole, decr.AUC with rifampicin, enhanc.eff.  Haloperidol.
                                                              Indications: Schizophren., mania, hypomania, organ. psychos.,
   tens., anticholinerg./ meds.with anticholinerg.activ., anticholinerg.   with Li/tryptophan.
   effs.of antihistam.potent., antidyskinet., sedat.& anticholinerg.eff.of   See also MDR page 476.  agitat.in psychot.illn., short term treatm.of childr.behav.disords.not
                                                              respond.to psychotherapy/meds.other than neurolept., motor. tics &
   TCA’s/ haloperidol/ loxapine/maprotiline/molindone/ phenothiazine/   MOLIPAXIN, Sanofi-Aventis [P/S]
   pimozide or thioxanthines poss. prolong. & intensif., ser.conc.of digox.  Trazodone HCl.  voc.utter.of Tourette’s syndr.
                                                              (S5) TABS, [P/S] G/2.6.5/96
   incr., phenytoin & poss.other hydantoin anticonvuls. plasma conc.incr.  Indications: Depress., mixed anx.& depress.
   See also MDR page 159.       (S5) CAPS.E/1.2/ 9, E/1.2/ 10.  763454-001: 5 mg, 100, R561,20
                                                              (S5) CAPS, [P/S] B/2.6.5/10.
   BIOTECH TRAZODONE, Biotech [P/S]  744417-007: 50 mg, 100, R545,94  763411-019: 0,5 mg, 60, R121,96
   Trazodone HCl.               744425-018: 100 mg, 100, R1 045,49  Dosage: Indiv. Adults: Usual dos: 0,5-5 mg 2-3xdly.
   Indications: Depress., mixed anx.& depress.  Dosage: Indiv.dos.accord.to sev.of condit.& pt’s.respons. Admin.  Sev.psychos./resist.pts: dos.of up to 100 mg dly may be reqd. High
   (S5) CAPS, 43/1.2/0698, 0699  in 3 div.dos.                dos.therapy of 200 mg dly has been used. Reduc.to low.eff.maint.dos.
                                           st
   720200-001: 50 mg, 100, R367,45  Depress: 150 mg dly.1  week, incr.to 300 mg/day or high.acc.  Childr. over 3 yrs: Maint.dos: 0,025-0,05 mg/kg bw/day in 2-3 div.
   720201-001: 100 mg, 100, R734,90  to clinic.respons. (600 mg/day dos.has been report.) Optim.dos.  dos. When contr.not urgent init.at ½ above level work.up to maint.
   Dosage: Dly.dos.admin.in 3 div.dos.  betw.300-400 mg/day.  dos. Dly dos.may be incr. as need.& tol.by 0,5 mg increm.at 5-7 day
   Adults: Depress: Optim.dos: 300-400 mg/day. Suggest.init dos:   Mild anx.& depress: Init.dos.100-150 mg/day, if depress.is predom.  interv. up to max. 0,150 mg/kg bw/day.
   150 mg/day in1st wk.incr.to 300 mg/day or high.accord.to clinic.re-  sympt., 300-400 mg/day may be requir.  (S5) INJ, [P/S] B1541, K/2.6.5/72.
   spons.(600 mg dos.report.).  Contraindications: Combin.use with other psychotrop. drugs should   763462-005: 5 mg/ml, 5x1 ml, R218,54.
   Mix.anx.& depress: Recomm.init.dos: 100-150 mg/ day. When   only be undertak.with due recognition of the poss.of potentiat., con-  763470-008: 20 mg/2 ml, 5x2 ml, R377,35
   depress.is predomin.sympt dly.dos.of 300-400 mg poss.reqd.for   com. apraclonidine./brimonidine., safety in pregn.not est., childr.  Dosage: Ac.psychot.condits: Adults: Admin. IM 2-10 mg. Subseq.
   satisfact. respons.          Side effects: CNS eff., serotonin syndr.with convuls., GI disturbs.,   dos.may be given hrly. until sympts.contr.although interv.of 4-8 hrs.
   Contraindications: Ac.recov.phase of MI, combin. use with other   dry mouth, weight loss, weakn., tachycard., hypertens., blurr. vision.,   may be adeq. Up to 30 mg IMI may be reqd.for emerg.
   psychotrop.drugs should only be undertak.with due recognition of   skin rash., priapism.  Contraindications: Parkinson’s, sev.tox.CNS depress., comatose
   the poss. of potent., safety in porphyr/pregn./lactat.& childr.not est.  Drug interactions: Potent act.of barbits.musc. relax./ volatile   states, bone marr.suppress., phaeochromocyt., safety in pregn.&
   Side effects: CNS effs., dizzin., headache, drowsiness. dry mouth,   anaesth./sedat.& anti-depress. incl. alcoh., poss.interacts with MAO-  lactat.not est., childr. und.3 yrs., caut./not at all in imp.liv., kidn., CV,
   GI disturbs., unpleas.taste, hypotens., allerg.reacts., fast/slow heart   Is report., neurotox. S/E poss.promote with concurr.tricycl./ relat. anti-  cerebrovasc.& resp.funct., clos.angle glauc., diab. mellit., hypothy-
   beat, priapism, tremors, unus.excitem., confus., blurr. vis., musc.trem.,   depress.& Li, amiodarone incr.risk of ventric. arrhythm., elev.ser.lev.  roid., myasth.grav., prostat. hypertrophy.
   arthralg., unusual tiredn./weakn., bld.dyscras., jaund., hepatocell.  of digox./phenytoin, trazodone, anti-convuls.effs.of antiepilept.poss.   Side effects: Tard.dyskines.in elderly, dur.long-term ther./aft.withdr.,
   damage, weight loss, hyponatraem.poss.due to inappropr.secret.of   antagon., occas.reports of seroton.syndr.& convuls. esp. when assoc.  sudd.& unexpect.death, neurolog. effs.esp.extrapyramid.syndr., addit.
   antidiuret.horm.esp.elderly, skin rash.  with other psychotrop.meds.  CNS effs., skin/eye pigment deposit.with prolong.use, corn. & lens</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page52.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page48.html">48</a>&nbsp;&nbsp;&nbsp;<a href="page49.html">49</a>&nbsp;&nbsp;&nbsp;<a href="page50.html">50</a>&nbsp;&nbsp;&nbsp;<a href="page51.html">51</a>&nbsp;&nbsp;&nbsp;<a href="page52.html">52</a>&nbsp;&nbsp;&nbsp;<a href="page53.html">53</a>&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>
             </td>
             <td width="35%"><a href="page54.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page54.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
